Project 1 builds on our preliminary data and recent reports in the literature that have identified a series of biomarkers of a pro-inflammatory immune response and of immunosuppression in both tumor tissue and in circulating blood that have promising therapeutic predictive and disease prognostic value in melanoma patients treated with immunotherapy. These will be simultaneoulsy evaluated as part of E1609 trial testing adjuvant ipilimumab at high dose and standard dose versus IFN? in patients with operable stage IIIB/C and M1a/b melanoma. This project will have 3 aims to be tested within each of the E1609 trial cohorts:
Aim 1 : Circulation. (1a) Circulating cellular populations: test the hypothesis that baseline and/or early on-treatment IFNg+CD4+ and IFNg+CD8+ antigen specific T-cell immunity as well as specific host suppressor elements (defined populations of regulatory T cells and myeloid-derived suppressor cells) correlate with clinical outcome (RFS and OS), (lb) Circulating serum biomarkers: test the hypothesis that baseline and/or earty on-treatment pro-inflammatory cytokine and chemokine profiles correlate with clinical outcome.
Aim 2 : Tumor and tumor microenvironment: First, test the hypothesis that a pretreatment, pro-inflammatory, tumor microenvironment (high baseline expression levels of immune-related genes) correlates with clinical outcome (RFS and OS). As secondary sub-aims, we will test the association of the tumor mutational status (BRAF, NRAS and wild-type status for both) and clinical outcome. We will also assess the predictive value of the methylation levels of immune-related genes.
Aim 3 : Based on the common systems biology, an overall model analysis will be developed to link markers of interest in Aims 1 and 2 (linking significant markers in the circulation with those in the tumor microenvironment) where we hypothesize that a pro-inflammatory therapeutically predictive signature(s) of biomarkers will be identified and validated within each of the trial arms. We expect overlapping predictive models for ipilimumab and HDI based on the common systems biology.

Public Health Relevance

The current paradigm of adjuvant therapy in melanoma involves the indiscnminate treatment of all patients clinically considered at high risk for melanoma recurrence and mortality, despite data showing that only a small proportion of patients will benefit. This research seeks to identify biomarkers that can accurately predict which patients will respond to available treatment and who will be among those who could be spared the adverse events and cost due to lack of predicted efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-07
Application #
8933146
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2006-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$269,662
Indirect Cost
$94,996
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Dulmage, B O; Feng, H; Mirvish, E et al. (2015) Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol 172:1449-51
Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFR? up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41
Tarhini, Ahmad A; Edington, Howard; Butterfield, Lisa H et al. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Tarhini, Ahmad A; Shin, Donghoon; Lee, Sandra J et al. (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 24:150-7
Pancoska, Petr; Kirkwood, John M; Bouros, Spyros et al. (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375
Tarhini, Ahmad A; Lin, Yan; Yeku, Oladapo et al. (2014) A four-marker signature of TNF-RII, TGF-?, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 12:19
Geskin, Larisa J; Akilov, Oleg E; Lin, Yan et al. (2014) Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 23:598-600
Schowalter, Michael K; Dulmage, Brittany O; Ho, Jonhan et al. (2014) Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res 24:397-400
McArthur, Grant A; Chapman, Paul B; Robert, Caroline et al. (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-32

Showing the most recent 10 out of 59 publications